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Homozygous carriers of the 
TCF7L2 rs7903146 T-allele show 
altered postprandial response in 
triglycerides and triglyceride-rich 
lipoproteins
L. Engelbrechtsen1,2, T. H. Hansen1, Y. Mahendran1,2, P. Pyl1, E. Andersson1, A. Jonsson1, 
A. Gjesing1, A. Linneberg3,4,5, T. Jørgensen3,6,7, T. Hansen1 & H. Vestergaard1,8
The TCF7L2 rs7903146 T-allele shows the strongest association with type 2 diabetes (T2D) among 
common gene variants. The aim of this study was to assess circulating levels of metabolites following 
a meal test in individuals carrying the high risk rs790346 TT genotype (cases) and low-risk CC genotype 
(controls). Sixty-two men were recruited based on TCF7L2 genotype, 31 were TT carriers and 31 
were age- and BMI-matched CC carriers. All participants consumed a test meal after 12 hours of 
fasting. Metabolites were measured using proton nuclear magnetic resonance (NMR) spectroscopy. 
Metabolomic profiling of TCF7L2 carriers were performed for 141 lipid estimates. TT carriers had lower 
fasting levels of L-VLDL-L (total lipids in large very low density lipoproteins, p = 0.045), L-VLDL-CE 
(cholesterol esters in large VLDL, p = 0.03), and L-VLDL-C (total cholesterol in large VLDL, p = 0.045) 
compared to CC carriers. Additionally, TT carriers had lower postprandial levels of total triglycerides (TG) 
(q = 0.03), VLDL-TG (q = 0.05, including medium, small and extra small, q = 0.048, q = 0.0009, q = 0.04, 
respectively), HDL-TG (triglycerides in high density lipoproteins q = 0.037) and S-HDL-TG (q = 0.00003). 
In conclusion, TT carriers show altered postprandial triglyceride response, mainly influencing VLDL and 
HDL subclasses suggesting a genotype-mediated effect on hepatic lipid regulation.
Variants within the transcription factor 7-like 2 gene (TCF7L2) are the strongest genetic risk factors associated 
with development of type 2 diabetes (T2D)1. Several variants within this gene have been shown to increase 
the risk of diabetes by 30–50%; in which the rs7903146 has the largest and most consistent effect on diabetes 
susceptibility1.
Transcription factor 7-like 2 (TCF7L2) is involved in the Wnt signaling pathways in various tissues includ-
ing muscle, fat, liver and brain cells. Carriers of TCF7L2 risk variants have decreased insulin production, β -cell 
dysfunction and altered hepatic gluconeogenesis, possibly influenced by modulation of the incretin response2–6. 
The biological mechanism mediating these alterations is largely unknown, yet altered expression or splicing of 
TCF7L2 has been suggested as a likely mechanism. Several studies have assessed the effect of the high risk T-allele 
on expression levels of TCF7L2 in different tissues. Reduced expression of TCF7L2 was reported in beta-cells 
from diabetic islets from T allele carriers7, while a marked increase in TCF7L2 mRNA in human pancreatic islets 
was found8. However, the T allele does not seem to have an effect on the expression of TCF7L2 in skeletal muscle 
and adipose tissue9.
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Recently, Norton et al. demonstrated that silencing of TCF7L2 in hepatocytes led to changes in the expression 
of 406 genes including key regulators of cellular growth, differentiation, and of amino acid, lipid and glucose 
metabolism in hepatocytes10, suggesting that TCF7L2 may mediate a variety of actions in hepatocytes including 
changes in lipid metabolism. Additionally, a meta-analysis including 24 studies with 52,575 individuals demon-
strated that the minor T-allele was associated with lower triglyceride levels in individuals with T2D11. Thorough 
examination of the human metabolome following an oral glucose tolerance test in 15 high risk and 15 low risk 
homozygous TCF7L2 variant carriers revealed no differences among T and C allele carriers12, whereas an intra-
venous glucose tolerance test revealed changes in plasma sphingomyelins, phosphatidylcholines and lysophos-
phatidylcholines species in T allele carriers13.
Based on these findings, we aimed to perform a deep characterization of the changes that occur in lipid metab-
olites during a meal test in TCF7L2 variant carriers by using a nuclear magnetic resonance spectroscopy (NMR) 
platform. We hypothesized that normoglycemic homozygous T-allele carriers have alterations in their lipid profile 
reflecting a genotype-mediated effect on lipid metabolism, which arises prior to glucose intolerance and diabetes.
Results
Metabolite changes were observed during a standardized meal test among 31 CC carriers and 31 TT carriers. 
Groups were age and BMI matched and no significant differences between the groups were found in the above-
mentioned measures (Table 1).
Metabolomic profiling of plasma samples at the 16 time points were completed for 141 lipid metabolites. 
Fasting levels of lipid estimates were compared using Wilcoxon rank sum test, however, only L-VLDL-L (total 
lipids in large VLDL, p = 0.045), L-VLDL-CE (cholesterol esters in large VLDL, p = 0.03), and L-VLDL-C (total 
cholesterol in large VLDL, p = 0.045) and LA:FA (ratio of 18:2 linoleic acid to total fatty acids, p = 0.048) were 
significantly different between the groups, with TT carriers exhibiting the lowest concentrations. Especially at the 
final stage of the meal test (240 min), TT carriers had lower levels of XS-VLDL-TG (triglycerides in extra small 
VLDLs, p = 0.006), S-HDL-TG (triglycerides in small HDLs, p = 0.006), LDL-TG (total triglycerides in LDLs, 
p = 0.038) and IDL-TG (total triglycerides in IDLs, p = 0.005). Overall there seemed to be a trend towards lower 
lipid levels in TT carriers at 240 min in many lipid fractions including S-VLDLs and S-HDLs (Fig. 1).
Mixed linear models demonstrated significant effects of the genotype on the rate of change in lipid levels 
during the mixed meal test. The rate of change of 39 lipid metabolites was different among groups at a FDR of 5% 
(Supplementary Table 1), while 9 reached Bonferroni-corrected significance (Table 2). TT carriers had lower post-
prandial levels of total triglycerides (q = 0.03), lower concentration of triglycerides in VLDL (q = 0.05),(medium, 
small and extra small sized, q = 0.048, q = 0.0009, q = 0.04, respectively)), lower concentration of triglycerides 
in small HDL particles (q = 0.00003), and lower ratio of monounsaturated fatty acids/total fatty acids (MUFA/
FA, q = 0.006). In order to test if TCF7L2 regulate lipid levels in an insulin independent manner, we compared 
mixed models with and without adjustments for insulin by an anova. We found minor changes in p-values, but 
no changes in significance levels.
Dynamic response curves of total triglycerides, VLDL-TG and HDL-TG are depicted in Fig. 2.
Discussion
In this study, we present the effects of the minor T-allele of TCF7L2 rs7903146, the strongest T2D susceptibility 
gene variant, on postprandial lipid responses in homozygous carriers. Using a metabolomics platform allowing 
deep characterization of metabolite profiles, we demonstrate that TT carriers have significantly altered post-
prandial lipid response in addition to the previously established effect on glucose metabolism. The rate of change 
Variable TT-carriers CC-carriers p-value
Age (years) 53.3 ± 6.3 53.6 ± 6.9 0.7
BMI (kg/m2) 25.7 ± 2.5 26.3 ± 3.1 0.1
Waist-hip ratio 0.9 ± 0.1 0.9 ± 0.04 1.0
HOMA IR 9.6 ± 6.2 9.9 ± 6.1 1.0
Glucose (mmol/l) 5.7 ± 0.44 5.53 ± 0.37 0.1
Insulin (mmol/l) 36.4 ± 18.3 43.2 ± 25.5 0.2
ALAT (mmol/l) 3.18 ± 0.49 3.26 ± 0.42 0.5
Exercise (self-reported, 
excluding work) Inactive 
or < 2 h/week (very light 
exercise) 
1 (3%) 0 1.0
2–4 h/week (light exercise) 17 (55%) 17 (55%) 1.0
> 4 h/week of moderate 
exercise or 2–4 h/week of 
moderate exercise 
12 (39%) 14 (45%) 0.80
> 4 h/week of vigorous 
exercise 1 (3%) 0 1.0
Table 1.  Baseline characteristics of study participants. Data expressed as means ± SD or n(%). 
Concentrations were measured at fasting. Demographic description of study participants have been published 
previously13. Glucose, insulin and ALAT were log transformed prior to analysis. Statistical analyses used were 
students T test and Fishers exact test.
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Figure 1. Differences in lipid response among CC and TT carriers during a meal test. A Wilcoxon Man-
Whitney test was performed in each metabolite for each relative change, comparing the distributions between 
the two genotype of patients (CC and TT). The Heatmap visualises the resulting p-values for a selection of 
metabolites with significant differences (p < 0.05) at at least one of the time points. The actual p-values are 
overlaid as text with darker colour indicating more significant p-values. Time points reflect the difference in 
metabolite levels from the previous time point and compared between the groups. P-values are calculated by 
wilcoxon rank sum test. MUFA.FA: Ratio of monounsaturated fatty acid to total fatty acids; FAw6.FA: Ratio of 
omega 6 fatty acids to total fatty acids; FAw3.FA: Ratio of omega-3 fatty acids to total fatty acids; LA.FA: Ratio 
of 18:2 linoleic acid to total fatty acids; DHA.FA: Ratio of 22:6 docosahexaenoic acid to total fatty acids; LA: 
18:2 linoleic acid; FALen: Estimated description of fatty acid chain length; ApoB.ApoA1: Ratio of ApoB and 
ApoA1; S.: small sixed; M.: Medium sized; L.: Large size; XL.: extra large size; XXL: Chylomicrones; VLDL: 
very low density lipo proteins, LDL: low density lipoproteins; IDL: Intermediate density lipoproteins; HDL: 
High density lipoproteins;.TG = Concentration of triglycerides in the lipoprotein;.C = Total cholesterol in 
the lipoprotein;.P = Total concentration of the lipoprotein;.CE = Concentration of cholesterolesters in the 
lipoprotein;.FC = Free cholesterol in the lipoprotein;.L: Total lipids in the lipoprotein; HDL3.C: Total cholesterol 
in HDL3; HDL2.C; Total cholesterol in HDL2; HDL.D: Mean diameter for HDL particles.
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(concentration/min) of several subclasses of lipid particles are lower in high risk TT carriers during a meal test, 
with a strong effect on triglyceride levels suggesting a genotype-mediated effect on postprandial triglyceride 
regulation.
Several studies have suggested an association between TCF7L2 rs7903146 and dyslipidemia14–17, and recently 
a meta-analysis including 24 studies with 52,575 individuals demonstrated that the minor T-allele was associ-
ated with lower triglyceride levels in individuals with T2D11. Despite a high number of study participants, the 
meta-analysis was unable to demonstrate an association between the T-allele and triglyceride levels in nondia-
betic carriers.
In the present study, we report that normoglycemic homozygous T-allele carriers have marked alterations in 
their postprandial lipid response following a meal test. We demonstrate that T-allele carriers have lower postpran-
dial triglyceride-rich lipoproteins, with levels of VLDL-TG (x-small, small and medium), HDL-TG (small) and 
total triglycerides in plasma reaching statistical significance. Our results are diverging from two previous studies. 
Perez-Martinez et al. found that young male carriers of the rs7903146 T-allele have lower HDL and Apo A1 
response to a saturated fatty acid-rich meal, while healthy elderly persons have higher levels of plasma cholesterol 
and Apo B with accumulation of Apo B, cholesterol and triglycerides in small-triglyceride rich lipoproteins18. 
The studies may not be directly comparable since Perez-Martinez et al. used a fatty acid rich meal (65% fat, 10% 
protein and 25% carbohydrate), while this study used a standard breakfast meal (34% fat, 19% protein and 47% 
carbohydrate). Musso et al. found a higher incremental area under curve of triglycerides in healthy controls, 
suggesting altered postprandial triglyceride response in carriers of the T-allele. Similarly, Musso et al. used a 
Metabolites
TT-carriers CC-carriers
P FDR BonferroniFasting 240 min Fasting 240 min
Total Cholesterol 4.7 (3.1–6.3) 4.6 (2.9–6.5) 5.0 (3.0–6.6) 4.9 (3.0–6.9) 0.27 0.42 1
Total TG (mmol/l) 1.2 (0.6–2.5) 1.4 (0.5–3.3) 1.3 (0.5–2.7) 1.4 (0.4–3.2) 0.0002 0.005 0.030*
VLDLs
VLDL-TG (mmol/l) 0.9 (0.3–2.0) 1.0 (0.3–2.9) 0.9 (0.3–2.3) 1.0 (0.2–2.8) 0.0003 0.005 0.05*
XL-VLDL-TG (mmol/l) 0.04 (0.0–0.2) 0.05 (0–0.3) 0.04 (0.0–0.2) 0.05 (0–0.2) 0.009 0.04 1
L-VLDL-TG (mmol/l) 0.2 (0.02–0.5) 0.2 (0.01–0.8) 0.2 (0.01–0.6) 0.2 (0–0.8) 0.001 0.01 0.20
M-VLDL-TG (mmol/l) 0.3 (0.1–0.7) 0.3 (0.1–1.0) 0.3 (0.09–0.8) 0.3 (0.1–1.0) 0.0003 0.005 0.048*
S-VLDL-P (mol/l)
3.5 × 10−8 
(1.9–
5.4 × 10−8)
3.6 × 10−8 
(1.8–
6.1 × 10−8)
3.6 × 10−8 
(2.0–
6.1 × 10−8)
3.7 × 10−8 
(1.8–
6.3 × 10−8)
0.0002 0.005 0.031*
S-VLDL-TG (mmol/l) 0.3 (0.1–0.5) 0.3 (0.1–0.5) 0.2 (0.1–0.5) 0.3 (0.09–0.5) 5.98 × 10−6 0.0005 0.0009*
XS-VLDL-TG (mmol/l) 0.1 (0.06–0.2) 0.1 (0.05–0.2) 0.1 (0.06–0.2) 0.1 (0.05–0.2) 0.0003 0.005 0.044*
LDLs
L-LDL-TG (mmol/l) 0.09 (0.05–0.12) 0.08 (0.04–0.1)
0.09 
(0.05–0.15) 0.08 (0.05–0.2) 0.52 0.67 1
M-LDL-TG (mmol/l) 0.04 (0.01–0.05)
0.03 
(0.009–0.6)
0.04 
(0.02–0.06)
0.03 
(0.01–0.07) 0.34 0.50 1
S-LDL-TG (mmol/l) 0.02 (0.007–0.04)
0.02 (0.004–
0.04)
0.02 
(0.01–0.04)
0.02 (0.007–
0.04) 0.007 0.034 1
HDLs
HDL-TG (mmol/l) 0.12 (0.08–0.16) 0.1 (0.08–0.2)
0.12 
(0.08–0.19) 0.1 (0.08–0.2) 0.0002 0.005 0.037*
XL-HDL-TG (mmol/l) 0.017 (0.01–0.03)
0.02 
(0.01–0.03)
0.017 
(0.01–0.03) 0.02 (0–0.03) 0.07 0.15 1
L-HDL-TG (mmol/l) 0.02 (0.01–0.04)
0.02 
(0.01–0.04)
0.03 
(0.02–0.05)
0.03 
(0.01–0.05) 0.43 0.59 1
M-HDL-TG (mmol/l) 0.04 (0.02–0.05)
0.03 
(0.01–0.06)
0.04 
(0.02–0.07)
0.03 
(0.01–0.07) 0.007 0.034 1
S-HDL-TG (mmol/l) 0.04 (0.03–0.06)
0.04 
(0.02–0.07)
0.04 
(0.02–0.08)
0.04 
(0.02–0.08) 1.78 × 10
−7 2.83 × 10−5 2.83 × 10−5*
Fatty acids
Total fatty acids 11.5 (7.7–15.5) 11.7 (7.1–17.6) 12.1 (8.0–15.9) 12.2 (7.7–16.4) 0.056 0.15 1
MUFA 2.9 (1.6–4.5) 2.9 (1.3–5.4) 2.9 (1.8–5.4) 3.0 (1.8–5.8) 0.003 0.016 0.445
MUFA/FA (%) 25.3 (20.4–31.7) 25.1 (18–31.8)
25.4 
(21.1–34.3) 25.5 (16–35.1) 3.72 × 10
−5 0.002 0.006*
PUFA 4.5 (3.1–5.7) 4.4 (2.8–5.7) 4.5 (3.1–5.7) 4.5 (2.9–6.2) 0.25 0.40 1
Table 2.  Metabolite responses to a meal test in TT and CC carriers of the rs7903146 TCF7L2. Data is 
expressed as median (range) at fasting and at 240 min after ingestion of a meal. Mixed models were used for 
calculation of p-values, comparing the postprandial metabolite responses from 0 min to 240 min. P-values 
are crude values. FDR states p-values adjusted for a false discovery rate of 5%, and Bonferroni is the p-values 
corrected for multiple testing by Bonferroni correction. S = small size, M = medium size, L = large size, XL = extra 
large size. TG = triglycerides. MUFA = Monounsaturated fatty acids. PUFA = Polyunsaturated fatty acids.
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high fat meal (the amount of fat was based on body surface area with 78.3 g fat, 55.6% saturated fatty acids, 29.6% 
monounsaturated fatty acids, 4.2% polyunsaturated fatty acids, 0.5 g cholesterol per m2)19. Subsequently, dissimi-
larities in postprandial triglyceride response between our and previous studies may be related to the study design 
and choice of meal test. However, it was recently demonstrated that the fat content in a meal test is not directly 
associated with postprandial triglyceride response20.
We found minor differences between CC and TT carriers in fasting lipid levels (Ratio of LA/FA, and levels 
of L-VLDL-L, -C and –CE) indicating that the majority of the genotype-mediated effect on lipids arise post-
prandially. The concentration of chylomicrons (measured as XXL-VLDL) did not show substantial difference 
between the groups, suggesting that the lower triglyceride levels among TT carriers are not caused by decreased 
intestinal uptake and transport of triglycerides from the intestine to the liver. Rather, the lower plasma levels of 
triglycerides in TT carriers may be liver-mediated and possibly influenced by uptake, synthesis or degradation of 
triglyceride-rich lipid particles.
A recent study by Norton et al. demonstrated that TCF7L2 in a time-dependent manner regulates the expres-
sion of 406 genes in hepatocytes10. Strong proximal TCF7L2 binding indicated direct regulation of 149 genes10. 
Silencing of TCF7L2 resulted in altered expression of multiple genes involved in lipid uptake, synthesis, storage 
and transport, indicating that reduced gene expression leads to increased synthesis of cholesterol and triglyc-
erides. Animal studies have suggested that TCF7L2 may regulate lipid levels through an insulin independent 
manner. In mice, with impaired Wnt signaling due to a LRP6 mutation, TCF7L2 expression is reduced, and 
the animals exhibit increased de novo lipogenesis and cholesterol synthesis leading to high plasma triglyceride 
levels21. Additionally, Boj et al. reported that newborn liver-specific TCF7L2 knockout mice have altered hepatic 
lipid metabolism with significantly lower serum levels of triglycerides and fatty acids6. In summary, animal 
Figure 2. Triglyceride levels during a mixed meal test among TT and CC carriers. Data is expressed as 
mean ± SEM.
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studies report an association between TCF7L2 and hepatic lipid regulation, although, the directionality of the 
effect is not clear. The expression and splicing of TCF7L2 is highly tissue-specific, and altered expression and 
alternative splicing of mRNA transcripts may influence the function of TCF7L2. This could provide an explana-
tion for the diverging results on triglyceride levels in knockout models22,23. To test the hypothesis that TCF7L2 
influence hepatic lipid regulation in an insulin independent manner we tested our mixed models with and with-
out adjustments for insulin levels. We found no changes in significance levels among the reported lipid fractions, 
which may to some extent, support the findings from animal studies that the role of TCF7L2 works in hepatic 
lipid regulation is independent of insulin.
Triglycerides are transported together with cholesterol in triglyceride-rich lipoproteins, including VLDLs, 
chylomicrons and corresponding remnants. Triglycerides have been associated with development of cardiovas-
cular disease; however, the causal relationship between triglycerides and development of atherosclerosis is still 
elusive24–26. It has been suggested, that triglycerides are not causing atherosclerosis but are rather a marker of 
the cholesterol-content in triglyceride-rich lipoproteins27,28. Nonetheless, triglyceride-rich lipoproteins are able 
to penetrate the arterial intima causing low-grade inflammation due to triglyceride hydrolysis and formation of 
macrophage foam cells, leading to increased risk of atherosclerotic cardiovascular disease26.
In this study, we report postprandial changes in lipids trying to mimic the daily physiologic excursions in 
lipid levels among TCF7L2 variant carriers. Indeed, the postprandial state may have substantial impact on risk of 
atherosclerosis since many hours daily are spend in the postprandial state. In line with this, previous studies have 
suggested that non-fasting triglyceride levels may be better predictors of cardiovascular disease risk than fasting 
levels of triglycerides27,29,30. This could indicate that non-diabetic carriers of the T-allele have a decreased risk of 
developing atherosclerosis and cardiovascular disease.
Yet, previous studies have found a positive association between the TCF7L2 rs790346 T- allele and develop-
ment of coronary artery disease (CAD) in diabetic patients17. Causality, however, is difficult to establish since T2D 
per se amplifies the risk of atherosclerosis and CVD31,32. Therefore, the association between the T-allele and CAD 
may not be accurate and further studies are needed to assess this association.
In conclusion, our study demonstrates the complexity in determining the exact role of TCF7L2 in human 
metabolism, since changes in expression may cause different or even diverging effects across tissues. Nonetheless, 
our detailed characterization of dynamic metabolite changes during a meal test, suggest that T-allele carriers have 
altered lipid metabolism, possibly mediating a protective effect against elevated triglycerides and triglyceride-rich 
particles, which may translate in to a decrease in risk of developing atherosclerosis.
Methods
Detailed description of the study design, experimental procedures and study participants have been published 
previously33. All participants were recruited in 2007 based on their TCF7L2 genotype from the population-based 
Inter99 study conducted at the Research Centre for Prevention and Health, Glostrup, Denmark34.
Study subjects. Sixty-two men were examined, 31 homozygous for the high risk TCF7L2 rs7903146 T allele 
(cases) and 31 age- and BMI-matched carriers of the low-risk TCF7L2 rs7903146 C allele (controls). All partici-
pants were glucose tolerant and had no concurrent medical conditions. All participants gave details on medica-
tion and prescriptions. Three individuals were treated for hypercholesterolemia, and four for hypertension.
Meal test. All participants consumed a test meal at 8:00 in the morning after approximately 12 hours of fast-
ing. The meal was consumed within 15 minutes. The mixed meal consisted of 50 g white bread, 50 g black bread, 
10 g butter, 40 g cheese, 20 g sugar-free jam and 200 ml milk (34% fat, 47% carbohydrate, 19% protein), com-
prising a total of 2,370 kJ (566 kcal). The mixed meal test was chosen to mimic a standard breakfast. Arterialised 
venous blood was drawn at 20, 10 and 0 min before and at 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 180, 210 and 
240 min after ingestion of the meal.
Blood samples. All blood samples were drawn prior to, during and after a meal test. Samples included EDTA 
plasma and were kept in a freezer at − 80 °C.
Metabolite profiling. Samples were analysed for levels of metabolites at the 16 time points including a full 
set of molecular measures quantified from native plasma by targeted NMR (nuclear magnetic resonance) profil-
ing. The high-throughput NMR platform (Brainshake Ltd, Helsinki, Finland) has previously been used in various 
epidemiological and genetic studies and details of the experimental protocols, including sample preparation and 
spectroscopy, have been described elsewhere35,36.
The NMR platform quantifies the number and size of lipoproteins, each expressed as a lipoprotein parti-
cle concentration (mmol/L, mol/L or g/L), or as an average particle size (nanometers). The concentrations of 
lipoproteins of different sizes were calculated from the measured amplitudes of their spectroscopically distinct 
lipid methyl-group NMR signals. Weighted-average lipoprotein particle sizes were derived from the sum of the 
diameter of each subclass multiplied by its relative mass percentage based on the amplitude of its methyl NMR 
signal35,36.
Metabolites assessed included 141 different lipid particles: lipoprotein particles and subclasses (chylomicrons, 
very large density lipoproteins (VLDL). intermediate density lipoproteins (IDL), large density lipoproteins (LDL), 
high density lipoproteins (HDL) particles), cholesterols (Total, VLDL, LDL, HDL, Free cholesterol and esterified 
cholesterol), glycerides and phospholipids (triglycerides in VLDL, LDL and HDL, diglycerides, phosphoglycer-
ides, phosphatidylcholine and sphingomyelins), apolipoproteins (ApoA1, ApoB, ApoB/ApoA1), fatty acids (total 
fatty acids, degree of saturation, docosahexaenoic acid, linoleic acid, omega-3-fatty acids, omega-6-fatty acids, 
polyunsaturated fatty acids, monounsaturated fatty acids, saturated fatty acids).
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Statistical analysis. Statistical analyses were performed using R, version 3.1.3 and 3.3.0 (http://
www.r-project.org). Data is expressed as medians (range: minimum to maximum) or means ± standard devi-
ation. Demographic variables were compared by either Fishers exact test (physical exercise) or student´s t test. 
Glucose, insulin and ALAT levels were log transformed prior to analysis. Insulin resistance was evaluated by 
the homeostatic model assessment of insulin resistance (HOMA- IR) in the fasting state (HOMA IR = (glucose 
(mmol/L) × insulin (pmol/L))/22.5). All fasting metabolite levels were compared at 0 minutes.
Metabolite levels during the meal test were compared using linear mixed models. All metabolites were 
pareto-scaled (divided by the square root of the standard deviation) prior to analysis. Linear mixed models were 
chosen to assess the effect of genotype on the course of the curve (time-genotype interaction) during the meal 
test from 0 to 240 min. Gaussian spatial correlation was used to model the covariance allowing metabolite meas-
urements that are temporally close together to be correlated to a higher degree than measurements further apart. 
Model assumptions were checked visually. False-discovery rates of 5% were applied to account for multiplicity. 
Similarly, the p-values were Bonferroni-corrected by multiplying by the number of comparisons (number of time 
points and metabolites, n = 2304). The mixed linear models were compared by an anova to mixed linear models 
adjusted for insulin levels in order to detect if significant findings were insulin-dependent.
After conducting the linear mixed models, we tested if there were any clustering of metabolites in relation 
to relative changes in concentrations of metabolites during the meal test. To do so, we visualized the relative 
changes of each metabolite and compared them by group. Absolute metabolite concentrations per time point 
were calculated by taking the log10 of the ratio to the mean (over all time points) for each metabolite and for 
each study participant. From those log-transformed ratios, the relative change to the preceding time point was 
calculated for all time points except the first (e.g. log10-ratio at 210 minutes - log10–ratio at 180 minutes). A 
Wilcoxon-Mann-Whitney test was performed to compare the relative changes of all metabolites by comparing 
the distributions between the two genotypes (CC and TT).
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